BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 27749256)

  • 1. A dual strategy to improve psychotic patients' compliance using sustained release quetiapine oral disintegrating tablets.
    Refaat A; Sokar M; Ismail F; Boraei N
    Acta Pharm; 2016 Dec; 66(4):515-532. PubMed ID: 27749256
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lipids bearing extruded-spheronized pellets for extended release of poorly soluble antiemetic agent-Meclizine HCl.
    Qazi F; Shoaib MH; Yousuf RI; Nasiri MI; Ahmed K; Ahmad M
    Lipids Health Dis; 2017 Apr; 16(1):75. PubMed ID: 28403892
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Taste-masked and affordable donepezil hydrochloride orally disintegrating tablet as promising solution for non-compliance in Alzheimer's disease patients.
    Liew KB; Tan YT; Peh KK
    Drug Dev Ind Pharm; 2015 Apr; 41(4):583-93. PubMed ID: 24495273
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Formulation, preparation, and evaluation of novel orally disintegrating tablets containing taste-masked naproxen sodium granules and naratriptan hydrochloride.
    Stange U; Führling C; Gieseler H
    J Pharm Sci; 2014 Apr; 103(4):1233-45. PubMed ID: 24532095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Orodispersible tablets containing taste-masked solid lipid pellets with metformin hydrochloride: Influence of process parameters on tablet properties.
    Petrovick GF; Kleinebudde P; Breitkreutz J
    Eur J Pharm Biopharm; 2018 Jan; 122():137-145. PubMed ID: 29106946
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Formulation and Evaluation of Baclofen-Meloxicam Orally Disintegrating Tablets (ODTs) Using Co-Processed Excipients and Improvement of ODTs Performance Using Six Sigma Method.
    Abdelmonem R; Abdellatif MM; Al-Samadi IEI; El-Nabarawi MA
    Drug Des Devel Ther; 2021; 15():4383-4402. PubMed ID: 34690500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel and discriminative method of in vitro disintegration time for preparation and optimization of taste-masked orally disintegrating tablets of carbinoxamine maleate.
    Liu Y; Li P; Qian R; Sun T; Fang F; Wang Z; Ke X; Xu B
    Drug Dev Ind Pharm; 2018 Aug; 44(8):1317-1327. PubMed ID: 29521132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quality by Design Approach for Development and Characterisation of Solid Lipid Nanoparticles of Quetiapine Fumarate.
    Agarwal S; Murthy RSR; Harikumar SL; Garg R
    Curr Comput Aided Drug Des; 2020; 16(1):73-91. PubMed ID: 31429691
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development and optimization of taste-masked orally disintegrating tablets (ODTs) of clindamycin hydrochloride.
    Cantor SL; Khan MA; Gupta A
    Drug Dev Ind Pharm; 2015; 41(7):1156-64. PubMed ID: 25000481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Application of a quality-by-design approach for utilizing sodium stearyl fumarate as a taste-masking agent in dextromethorphan hydrobromide orally disintegrating tablets.
    Mahrous GM; Ibrahim MA; Mostafa HF; Elzayat EM
    Pharm Dev Technol; 2019 Jul; 24(6):711-719. PubMed ID: 30714850
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preparation of orally disintegrating tablets with taste-masking function: masking effect in granules prepared with correctives using the dry granulation method and evaluation of tablets prepared using the taste-masked granules.
    Kawano Y; Ito A; Sasatsu M; Machida Y
    Yakugaku Zasshi; 2010 Jan; 130(1):81-6. PubMed ID: 20046070
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, development and in-vitro evaluation of diclofenac taste-masked orodispersible tablet formulations.
    Guhmann M; Preis M; Gerber F; Pöllinger N; Breitkreutz J; Weitschies W
    Drug Dev Ind Pharm; 2015 Apr; 41(4):540-51. PubMed ID: 24495274
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Investigation on the effect of polymer and starch on the tablet properties of lyophilized orally disintegrating tablet.
    Liew KB; Peh KK
    Arch Pharm Res; 2021 Aug; 44(8):1-10. PubMed ID: 25579848
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Original research paper. Formulation and pharmaceutical development of quetiapine fumarate sustained release matrix tablets using a QbD approach.
    Gavan A; Porfire A; Marina C; Tomuta I
    Acta Pharm; 2017 Mar; 67(1):53-70. PubMed ID: 28231048
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enalapril maleate orally disintegrating tablets: tableting and in vivo evaluation in hypertensive rats.
    Tawfeek HM; Faisal W; Soliman GM
    Pharm Dev Technol; 2018 Jun; 23(5):496-503. PubMed ID: 28489472
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Further improvement of orally disintegrating tablets using micronized ethylcellulose.
    Okuda Y; Irisawa Y; Okimoto K; Osawa T; Yamashita S
    Int J Pharm; 2012 Feb; 423(2):351-9. PubMed ID: 22138608
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of screw configuration and polymeric carriers on hot-melt extruded taste-masked formulations incorporated into orally disintegrating tablets.
    Morott JT; Pimparade M; Park JB; Worley CP; Majumdar S; Lian Z; Pinto E; Bi Y; Durig T; Repka MA
    J Pharm Sci; 2015 Jan; 104(1):124-34. PubMed ID: 25410968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative study of different approaches for preparation of chlorzoxazone orodispersible tablets.
    Moqbel HA; ElMeshad AN; El-Nabarawi MA
    Drug Dev Ind Pharm; 2017 May; 43(5):742-750. PubMed ID: 27534668
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development and evaluation of orally disintegrating tablets comprising taste-masked mirtazapine granules.
    Yıldız S; Aytekin E; Yavuz B; Bozdağ Pehlivan S; Vural İ; Ünlü N
    Pharm Dev Technol; 2018 Jun; 23(5):488-495. PubMed ID: 28368673
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Formulation and evaluation of meloxicam oral disintegrating tablet with dissolution enhanced by combination of cyclodextrin and ion exchange resins.
    Samprasit W; Akkaramongkolporn P; Ngawhirunpat T; Rojanarata T; Opanasopit P
    Drug Dev Ind Pharm; 2015 Jun; 41(6):1006-16. PubMed ID: 24865111
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.